Semaglutide Supply Pause
Dr. Reddy's Pauses Semaglutide Injections After Active Ingredient Quality Issue
Key Points
Dr Reddy's AGM is scheduled for July 23, 2026, at 11:00 a.m. IST via video conferencing, with a proposed final dividend of ₹8 per equity share for FY2025-26 and the notice expects the dividend to be paid by July 30, 2026; the meeting will also consider re‑appointment of director K Satish Reddy and the appointment of Deloitte Haskins & Sells LLP as statutory auditors for five years.
Dr Reddy's describes its GLP-1 strategy with the aim of being a 'full-stack player' in the metabolic-therapy space, noting its Obeda brand in India and expansion into Canada as part of this approach.
The Hyderabad-based company’s July 9, 2026 update on semaglutide includes a market reaction where shares fell about 2.6% in early trading after the pause in supplies was announced.
The update about batches being out of specification due to an API issue and the ongoing root-cause investigation was disclosed in an exchange filing, signaling an official regulatory communication rather than a press release alone.
Dr. Reddy's Laboratories has halted commercial supplies of its semaglutide injections after internal quality checks found batches out of specification, according to Yahoo Finance. The problem stems from an issue with the active pharmaceutical ingredient, or API — the core chemical that makes the drug work. Shares fell about 2.6% in early trading on July 9, 2026, after the company disclosed the pause in an official exchange filing.
The Hyderabad-based drugmaker says patient safety is not at risk and that its global regulatory filings remain valid. Supplies will stay on hold while the company investigates the root cause of the API discrepancy.
Batches Fail Internal Quality Checks, Investigation Underway
Dr. Reddy's found that certain semaglutide batches did not meet required quality standards. The fault lies with the active pharmaceutical ingredient — the key substance in the injection. The company reported the issue through an official exchange filing, signaling a formal regulatory disclosure rather than a routine press statement, according to Yahoo Finance.
The company has not said how many batches are affected or how long the pause will last. Management plans to answer investor questions about the issue on a conference call. No timeline for resuming supplies has been given publicly.
Shares Drop 2.6% as Markets React to Supply Pause
Dr. Reddy's stock fell about 2.6% in early trading after the announcement. Yahoo Finance reported shares dropped to around 1,324 rupees. Investors reacted quickly to the news that one of the company's key growth products would face a distribution delay of unknown length.
The semaglutide pause is a setback for a company that had been building momentum in the GLP-1 drug market. GLP-1 drugs are medicines that help control blood sugar and weight. Dr. Reddy's had been positioning itself as a major player in this fast-growing space.
Obeda Brand and Canada Expansion Now Disrupted
Dr. Reddy's has described its goal as being a 'full-stack player' in the metabolic therapy space. The company sells semaglutide under the Obeda brand in India and had recently expanded into Canada, according to Yahoo Finance. Both efforts are now disrupted while the supply pause continues.
The company says its existing regulatory filings around the world are still valid. That means it has not lost its approvals to sell the drug. But it cannot ship product until the API issue is resolved and batches pass quality checks again.
AGM Set for July 23 With Dividend and Auditor Vote Planned
The supply issue lands just weeks before Dr. Reddy's annual general meeting, scheduled for July 23, 2026, at 11:00 a.m. IST via video conference. Shareholders will vote on a proposed final dividend of ₹8 per equity share for the 2025-26 financial year. The dividend is expected to be paid by July 30, 2026.
The AGM agenda also includes the re-appointment of director K. Satish Reddy and a vote to appoint Deloitte Haskins & Sells LLP as statutory auditors for five years. Management will likely face sharp questions about the semaglutide halt from investors at the meeting.
Sentiment
Mostly NegativePublishers
38
Articles
166
Reach
204
